FDA Updates Foreign Operations - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Updates Foreign Operations



Budget issues and changing global markets are prompting FDA to revise its growing network of overseas offices. The agency is shutting down a small operation in Amman, Jordan, while expanding its presence in India. The Amman staff of two will move back to FDA headquarters to oversee the Middle East and North African medical product activities. Meanwhile, serious drug quality issues are prompting FDA to add seven people to its India office to ramp up drug inspections, bringing the total up to 19. And to better explain FDA policies and standards to local officials and manufacturers, FDA is appointing a native of Kashmir, Altaf Ahmed Lal, to head its India operations. Lal has been in the US for more than 30 years, recently at the US embassy in India. He will have to navigate charges from Indian officials and manufacturers of unwarranted US actions against Indian operators, along with complaints from US pharmaceutical companies that Indian patent decisions aim to bolster domestic firms at the expense of foreign manufacturers.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here